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Highlights 
 39 studies investigated HPA functioning as a predictor of antidepressant response 
 Non-responders did not differ from responders in pre-treatment CRH and ACTH 
 Non-responders had higher cortisol in studies with a specific methodological profile 
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Abstract 
Objective 
Although antidepressants are effective, around 50% of depressed patients are non-responsive. At the 
same time, some patients show alterations in the hypothalamic-pituitary-adrenal (HPA) axis. Due to 
interactions with central monoaminergic systems, these may profit less from antidepressants. 
Method 
To determine whether non-responders and responders differed in pre-treatment HPA axis functioning, 
the Cochrane Library, EMBASE, MEDLINE, and PsycINFO were searched. Studies using patients with 
depression being treated with antidepressants, and including both a pre-treatment HPA and a post-
treatment response measure were included. Standardised mean differences were calculated for meta-
analysis. 
Results 
Thirty-nine studies were included. Non-responders and responders did not differ in pre-treatment 
corticotropin-releasing hormone or adrenocorticotropic hormone. Meta-regression showed non-
responders had comparably higher pre-treatment cortisol in studies measuring cortisol non-invasively, 
not reporting sample storage, failing to control for age, and excluding patients with comorbidities. 
Conclusions 
Only studies with a specific methodological profile seem to be able to show that the more marked 
depressed patients’ alterations in the HPA axis, the less likely they are to profit from antidepressants. 
 
Keywords: antidepressant; cortisol; depression; hypothalamic-pituitary-adrenal axis; treatment 
response 
 
1. Introduction 
Antidepressants are among the most widely used first-line treatments for major depressive disorder 
(MDD); however, unfortunately, around 50% of patients are non-responsive to initial antidepressant 
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trials (Cleare et al., 2015). This raises the urgent question of which mechanisms underlie this 
phenomenon. One explanation is for there to exist subgroups of depressed patients, characterised by 
distinct pathophysiological profiles. 
One of the most consistent findings in MDD is of alterations in the hypothalamic-pituitary-adrenal 
(HPA) axis (de Kloet et al., 2007; Rohleder et al., 2010; Stetler and Miller, 2011; Waters et al., 2015). In 
healthy individuals, the HPA axis is characterised by both a marked diurnal rhythm (including an 
increase in cortisol upon awakening; Clow et al., 2010) and by its responsivity to a variety of stimuli 
(e.g., psychosocial stress; Skoluda et al., 2015). It is thus important to distinguish between basal and 
post-challenge HPA measures, the latter including both stimulation and suppression of the HPA axis. 
Upon stimulation, arginine vasopressin (AVP) and corticotropin-releasing hormone (CRH) are secreted 
by the paraventricular nuclei of the hypothalamus, which in turn initiate the synthesis of 
adrenocorticotropic hormone (ACTH) in the anterior pituitary (Nicolaides et al., 2015). 
Adrenocorticotropic hormone travels through the bloodstream to release the glucocorticoid cortisol in 
the adrenal cortex. This cascade is terminated by a negative feedback loop, whereby cortisol passes 
the blood-brain-barrier and suppresses the release of AVP, CRH and ACTH by attaching to 
mineralocorticoid (MR) and glucocorticoid receptors (GR). 
In MDD, there is evidence for multiple alterations along this axis, including elevated levels of 
CRH (Waters et al., 2015), elevated levels of ACTH and cortisol (Stetler and Miller, 2011), reduced 
glucocorticoid sensitivity (Rohleder et al., 2010), and MR/GR imbalance (de Kloet et al., 2007). These 
findings may shed light on the phenomenon of treatment non-response insofar as the HPA axis interacts 
with central monoaminergic systems, which in turn are targeted by antidepressants. For instance, CRH 
receptors are abundantly expressed in extra-hypothalamic areas, such as the raphe nuclei and the locus 
coeruleus, which constitute the major cell bodies of the serotonin (5-HT) and noradrenaline (NA) system, 
respectively (Valentino and Commons, 2005; Valentino and Van Bockstaele, 2008). Under conditions 
of acute stress, CRH can excite 5-HT neurons in the dorsal rape nucleus and modulate NA activity in 
the locus coeruleus by shifting the firing pattern from phasic to tonic (Joels and Baram, 2009). 
Glucocorticoids, via the MR and GR, are equally known to stimulate both the 5-HT and NA systems (de 
Kloet et al., 2005). Alterations in HPA functioning, as found in depressive disorders, are therefore likely 
to be paralleled by disturbances of this intricate interplay, which could in turn render affected individuals 
less likely to benefit from antidepressant treatment. 
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Taken together, a subgroup of depressed patients with alterations in the HPA axis may be less 
likely to respond to treatment with antidepressants. The aim of the present study was to find out whether 
non-responders could be distinguished from responders by means of HPA markers. To this end, we 
integrated previous studies on this topic using meta-analysis. In doing so, we provide the first 
comprehensive quantitative summary of this literature. We distinguished between HPA markers of 
central and peripheral origin, and between basal concentrations and concentrations obtained upon 
stimulation or suppression of the HPA axis and conducted separate meta-analyses for each category. 
An additional aim was to identify factors that contribute to study findings by using meta-regression. 
Based on a previous meta-analysis on the dexamethasone suppression test and antidepressant 
response (Ribeiro et al., 1993) and on a review on glucocorticoids as predictors of antidepressant 
response (Horstmann and Binder, 2011), we hypothesised that non-responders would have more 
marked pre-treatment HPA alterations when compared to responders. However, we hypothesised that 
this would only be found in studies controlling for illness severity (e.g., Juruena et al., 2009), the previous 
intake of psychotropic medication (Fischer et al., 2017a), and in those using a reliable (i.e., repeated or 
long-term) HPA measurement (e.g., Herane Vives et al., 2015). 
 
2. Method 
2.1 Search strategy 
Records were identified by searching the Cochrane Library, EMBASE, MEDLINE, and PsycINFO 
databases from the first available year until October 2015. Key words and subject headings were 
combined in accordance with the thesaurus of each database. The search string consisted of three 
components: 1) “HPA axis” and synonyms, including its components (e.g., “cortisol”), 2) “depressive 
disorder”, including synonyms, and 3) “antidepressant” and synonyms, including the most widely 
prescribed antidepressants (e.g., “citalopram”). All searches were restricted to research in humans. Only 
studies published in English, German, Dutch, French, Italian, or Spanish were to be included. 
 
2.2 Screening and selection procedure 
Records were screened regarding the following inclusionary criteria: 1) adult patients suffering from any 
depressive disorder (i.e., MDD, persistent depressive disorder) diagnosed according to the Diagnostic 
and Statistical Manual of Mental Disorders (DSM), the International Classification of Diseases (ICD), or 
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Research Diagnostic Criteria (RDC), 2) any kind of pre-treatment assessment of AVP, GR levels, CRH, 
ACTH, or cortisol, and 3) treatment including at least four weeks of continuous administration of 
monoamine oxidase (MAO) inhibitors, tri- or tetracyclic antidepressants, selective serotonin reuptake 
inhibitors (SSRIs), noradrenaline reuptake inhibitors (NRIs), serotonin-noradrenaline reuptake inhibitors 
(SNRIs), noradrenaline-dopamine reuptake inhibitors (NDRIs), or serotonin-noradrenalin-dopamine 
reuptake inhibitors (SNDRIs), and 4) standardised post-treatment symptom measure with a reported 
cut-off value dividing patients into non-responders and responders. Studies including bipolar patients 
were excluded, unless results were reported separately for unipolar and bipolar patients allowing for 
data to be extracted selectively. Comorbidity with somatic diseases, mental disorders, intake of 
medication upon study entry, and intake of medication pro re nata during the study were allowed, but 
recorded for meta-regression (see below). Studies delivering a mixture of different antidepressants or a 
combination of psychological and pharmacotherapy were included, but again, this was noted for 
subgroup analyses. Similarly, studies using response (e.g., a HAMD decrease of ≥ 50%) and/or 
remission (e.g., a HAMD score < 10) criteria were included and first analysed together and then 
separately. The search was complemented with a manual review of reference lists. 
 
2.3 Data extraction 
For each study, information was collected about the first author, its year of publication, the number of 
patients for which data were available for extraction, diagnostic procedures, diagnosis including subtype 
of depressive disorder, other sample characteristics (e.g., symptom severity), eligibility criteria (e.g., 
medication use upon study entry), pre-treatment assessment of HPA functioning, blinding to HPA-
related results, antidepressant treatment characteristics, response rates, and statistical analyses. Risk 
of bias was assessed by means of a modified version of a quality assessment tool that was used in two 
previous meta-analyses on cortisol as a predictor of psychological therapy response (Fischer and 
Cleare, 2017; Fischer et al., 2017b). Seven items were scored on a three-point scale (0-2). These 
included the number of used eligibility criteria, the adequacy of diagnostic procedures, the quality of the 
HPA axis assessment, the adequacy of the antidepressant treatment, the validity of the outcome 
assessment, the blinding procedure, and the use of relevant confounders in statistical analyses. The 
maximum attainable quality score was 14. 
 
2.4 Statistical analysis 
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To quantify the differences between non-responders and responders in HPA assessments at baseline, 
standardised mean differences were calculated based on mean values and standard deviations or 
based on frequency tables. This was done in accordance with the procedures outlined by Lipsey and 
Wilson (2001) and Borenstein et al. (2009). Whenever insufficient statistical parameters were reported, 
the authors were contacted. If it was not possible to gather additional data, the study was excluded. 
Hedge’s g was calculated from standardised mean differences to correct for small sample bias. Studies 
were weighed based on the inverse variance method (Borenstein et al., 2009; Lipsey and Wilson, 2001). 
Separate analyses were conducted for each HPA marker, and within individual markers for basal, 
stimulation, and suppression values. Aggregated effect sizes (ES) including a 95% CI were calculated 
using SPSS 22 and the macros developed by David B. Wilson 
(http://mason.gmu.edu/~dwilsonb/ma.html) Random rather than fixed effects meta-analyses were 
considered appropriate. 
Heterogeneity was indicated by means of Q and I2 statistics. Subgroup analyses were 
undertaken to study the effects of categorical variables, such as specific subtypes of depression 
(atypical, melancholic, persistent), different types of medication (MAO inhibitors, tri- or tetracyclic 
antidepressants, SSRIs, NRIs, SNRIs, NDRIs, SNDRIs), different challenges and different responder 
criteria on our results. Random effects meta-regressions were calculated to explore dichotomous and 
continuous sources of heterogeneity, but only when at least ten studies were available. Candidate effect 
modifiers were sex distribution (percentage of female patients; see e.g., Binder et al., 2009), symptom 
severity upon study entry (i.e., Hamilton Rating Scale for Depression score), the intake of psychotropic 
medication upon study entry (user percentage), single time point vs. aggregated HPA assessments, 
non-invasive (i.e., urine or saliva) vs. invasive (i.e., blood) measurement of cortisol, use of a naturalistic 
vs. standardised treatment approach, and the duration of treatment (number of weeks). In addition, each 
item of the quality assessment tool was tested in terms of being a potential predictor. Whenever at least 
ten studies were available, publication bias was to be examined by visual inspection of funnel plots and 
a trim and fill procedure (Duval and Tweedie, 2000). 
 
3. Results 
3.1 Search process 
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The search yielded 28,808 records, of which 511 were considered potentially relevant based on their 
title or abstract. Of these, 472 were excluded because they were not original research, were conducted 
in healthy people, included depressed patients with bipolar disorder, did not contain HPA measures, did 
not administer antidepressants, administered antidepressants for less than four weeks, used 
augmentation strategies, were retrospective in nature (e.g., cross-sectional comparison of treatment 
resistant patients vs. healthy controls), or did not divide patients into non-responders vs. responders 
based on a standardised symptom measure. It was not possible to obtain the necessary statistical 
parameters of seven studies. In total, 39 studies were eligible for data extraction. 
 
3.2 Characteristics of included studies 
Table 2 shows the main characteristics of the 39 included studies (see supplement 1 for a complete list 
of references). The first included study dated back to 1984 and the last one was published in 2015. The 
number of patients for which relevant data were available ranged from 5 to 290. Studies were weighted 
towards female participants, the average proportion being 63%. Most studies (n=26; 67%) did not 
indicate to which subtype of depression their patients belonged; three (8%) stated that their patients 
were non-psychotic and one indicated that all patients were non-atypical; the remainder used mixed 
subtypes or were confined to one specific subtype. More than half of the studies (n=25, 64%) used a 
severity cut-off as an inclusionary criterion (e.g., HAMD score ≥ 18). Nearly three quarters (74%) 
excluded at least some medical conditions, 64% excluded comorbidity with other mental disorders to 
some extent, and 69% excluded or washed out psychotropic drugs upon study entry. Nearly all studies 
published in the 1980s used the dexamethasone suppression test (DST; Carroll, 1982) to challenge the 
HPA axis and detect alterations in ACTH and cortisol, whereas studies conducted in the 1990s and 
2000s used a broad range of central and peripheral HPA parameters, and often reported both basal and 
post-challenge values. Amitriptyline was the most widely used antidepressant (11 studies, 28%), 
followed by citalopram/escitalopram and fluoxetine (both used in 6 studies, 15%). The majority of studies 
(n=27; 69%) used the Hamilton Rating Scale for Depression (HAMD) with a 50% minimum decrease in 
depressive symptoms as responder criterion. The average response rate was 56%, ranging from 31% 
to 91%. Nine studies (23%) used HAMD cut-off values as remitter criterion, and the average remission 
rate was 66% (range: 45%-91%). Quality ratings ranged from 2 to 10 (out of a maximum of 14), with an 
average of 6 points. 
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- Insert Table 1 here – 
 
3.3 Central predictors of treatment response 
In total, 11 studies looked at HPA parameters of central origin: AVP, CRH, and ACTH. As illustrated in 
Figure 1 (forest plot), non-responders tended to have lower initial concentrations of all central HPA 
markers when compared to responders (except for suppressed ACTH). However, meta-analysis, 
conducted for each parameter separately, did not find this to be significant: The one study measuring 
basal AVP did not find a difference between non-responders and responders to treatment; the same 
was true regarding basal CRH as measured in cerebrospinal fluid (n=2, mean ES=0.04, 95% CI [-0.79, 
0.87]); Z=0.09, p=0.927), basal ACTH (n=3, mean ES=0.16, 95% CI [-0.07, 0.39]; Z=1.38, p=0.168), 
and stimulated ACTH using the dexamethasone/CRH (Holsboer et al., 1987), metyrapone, or T3/TRH 
test (n=6, mean ES=0.11, 95% CI [-0.21, 0.42]; Z=0.66, p=0.510). Similarly, ACTH concentrations after 
suppression with dexamethasone were not linked with treatment response (n=3, mean ES=-0.14, 95% 
CI [-0.87, 0.60]; Z=-0.36, p=0.716). 
 
-Insert Figure 1 here- 
 
The Q and I2 statistics indicated low heterogeneity among studies measuring basal (Q=0.66, 
p=0.721, I2=0%) or stimulated ACTH (Q=4.12, p=0.533, I2=0%), and moderate to high heterogeneity in 
those measuring basal CRH (Q=1.87, p=0.171, I2=47%) or suppressed ACTH (Q=4.36, p=0.113, 
I2=54%). As noted above, there was rarely ever any information on which subtypes of depression were 
represented in the samples, which meant that diagnostic subgroup analyses were not feasible. 
Subgroup analyses for different pharmacological compounds were possible, but did not alter our 
findings, and neither did subgroup analyses for specific challenges or for studies using responder versus 
remitter criteria (data not shown). Due to the low number of studies using central HPA markers, it was 
not possible to undertake meta-regression. 
 
3.4 Peripheral predictors of treatment response 
A total of 36 studies measured HPA functioning via peripheral markers, that is, CBG (one study only) 
and cortisol. As can be seen in Figure 2 (forest plot), non-responders tended to have higher initial 
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concentrations of both peripheral HPA markers when compared to responders. However, meta-analysis, 
conducted for each parameter separately, again found this was not a significant difference. The only 
exception was the one study measuring basal CBG levels, which found significantly higher values in 
non-responders when compared to responders. Basal cortisol concentrations did not differ across the 
two groups (n=15, mean ES=-0.11, 95% CI [-0.30, 0.09]), Z=-1.09, p=0.277), and neither did stimulated 
(n=10, mean ES=-0.15, 95% CI [-0.50, 0.19]; Z=-0.86, p=0.392) or suppressed values (n=19, mean 
ES=-0.15, 95% CI [-0.41, 0.12]; Z=-1.08, p=0.279), the former including the dexamethasone/CRH, 
buspirone, bupropion, d-fenfluramine, and T3/TRH tests, and the latter including the dexamethasone 
and prednisolone suppression tests. 
 
-Insert Figure 2 here- 
 
Heterogeneity was low in studies using basal cortisol (Q=20.94, p=0.103, I2=33%) but moderate 
to high in studies using stimulated (Q=17.19, p=0.046, I2=48%) or suppressed cortisol (Q=40.58, 
p=0.002, I2=56%). As before, the investigation of diagnostic subgroups to explore sources of 
heterogeneity was halted due to missing information. When repeating meta-analyses within particular 
subgroups of antidepressant compounds, findings revealed that patients with higher basal cortisol 
concentrations responded significantly less well to venlafaxine (n=2, mean ES=-0.65, 95% CI [-1.16, -
0.15]; Z=-2.53, p=0.011). By contrast, subgroup analyses for specific challenges or for different 
responder criteria did not yield any significant findings (data not shown). 
Meta-regression revealed that studies measuring cortisol in urine or saliva (β=-0.62, p=0.004), 
not declaring how they stored samples (β=-0.61, p=0.007) and those not statistically controlling for age 
(β=-0.54, p=0.022) were more likely to find that non-responders had higher basal cortisol values when 
compared to responders. In addition, those who excluded patients with any comorbid somatic (β=-0.49, 
p=0.015) or mental (β=-0.59, p=0.002) illness were more likely to find higher cortisol values upon 
suppression in non-responders when compared to responders. No other significant effect modifiers were 
identified (data not shown). 
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4. Discussion 
This meta-analysis investigated whether HPA axis functioning predicts antidepressant treatment 
response in depressed patients. We report two main findings: First, non-responders and responders did 
not differ in any HPA markers of central origin, that is, AVP, CRH, or ACTH. Second, the same seemed 
to be true of cortisol, the main peripheral HPA marker. However, meta-regression revealed that studies 
measuring cortisol in urine or saliva, those not reporting sample storage conditions, those failing to 
statistically control for patients’ age, and those excluding patients with comorbidity were able to 
demonstrate that non-responders had significantly higher pre-treatment cortisol levels when compared 
to responders. 
A number of factors may account for the finding that neither AVP, nor CRH, or ACTH differed 
between non-responders and responders to antidepressant treatment, despite close interactions of the 
HPA and monoaminergic systems (Valentino and Commons, 2005; Valentino and Van Bockstaele, 
2008). For instance, it is important to note that basal levels of these parameters are usually determined 
by means of single time point measurements (e.g., blood sampling at 8 am). Indeed, all of the studies 
included here conformed to this procedure. Unfortunately, the reliability of this approach is limited by 
evidence showing great intra-individual variability of HPA markers due to state-like moderators, such as 
time of day or week-day (Skoluda et al., 2016). Another explanation for our null-findings could be the 
confounding of results by the invasive sampling methods used to obtain AVP, CRH, and ACTH (i.e., 
lumbar puncture). In favour of this, Weckesser et al. (2014) in a recent review showed that venepuncture 
is capable of activating the HPA axis in a substantial proportion of research participants. An unequal 
distribution of such subjects across studies may therefore have contributed to conflicting study results. 
Finally, the low number of studies using central HPA markers may have rendered it impossible to detect 
any significant group differences in central HPA markers in the first place. 
By contrast, we found basal cortisol to discriminate between non-responders and responders to 
antidepressants. However, this applied only to those studies that measured cortisol non-invasively, that 
is, in urine and saliva instead of blood. More specifically, non-responders had higher pre-treatment 
concentrations when compared to responders, which is in line with studies contrasting severely 
treatment-resistant patients with unipolar depression to healthy controls (Markopoulou et al., under 
revision). This means that patients suffering from hypercortisolaemia may overlap with those not 
achieving a sufficient clinical response. It is difficult to interpret the fact that confining our analysis to 
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studies not reporting sample storage conditions was also linked with positive findings. One explanation 
could be that authors choosing saliva sampling were less likely to explicitly describe sample handling, 
since saliva is relatively robust to the influence of environmental conditions (e.g., temperature). Plasma 
or serum samples, by contrast, require immediate action (e.g., centrifugation), which needs to be 
reported. Finally, studies failing to include age as a covariate in their statistical analyses were more likely 
to find significant group differences. One way to make sense of this is that very old patients have both 
higher cortisol levels (Miller et al., 2016; Van Cauter et al., 1996) and lower response rates to 
antidepressants (Cleare et al., 2015). Taken together, this suggests some of the positive results in the 
literature to be inflated by unadjusted statistical analysis. 
Cortisol after suppression with dexamethasone or prednisolone also appeared to be higher in 
non-responders to treatment with antidepressants; however only in studies which a priori excluded 
patients with any somatic illness influencing endocrine systems or comorbidity with other major metal 
disorders. Failure to suppress cortisol secretion after administration of synthetic analogues may be 
indicative of attenuated negative feedback sensitivity of the HPA axis (Carroll, 1982). This finding 
concurs with earlier studies contrasting severely treatment-resistant patients with healthy controls and 
finding that the former retained higher cortisol concentrations upon suppression (Juruena et al., 2013). 
It is not surprising that this only applied to studies without any major comorbidity, seeing that substance 
abuse, schizophrenia, and eating disorders are all paralleled by HPA alterations (Bradley and Dinan, 
2010; Chrousos, 2009). Including patients with additional illnesses may therefore have distorted cortisol 
values. More importantly, these illnesses themselves and/or additional medication may have interacted 
with patients’ response to dexamethasone or prednisolone. Thus, in this case, the higher quality studies 
did show higher post-suppression cortisol levels were associated with a poorer response to 
antidepressants. 
The present meta-analysis offers a number of strengths. It is the first quantitative summary of 
the literature on HPA functioning as a predictor of antidepressant treatment response. As such, it offers 
insight on whether one of the most frequently measured biological systems in depression is involved in 
the phenomenon of treatment-resistance, which affects around 50% of patients to some degree. Another 
strength is that the included studies are remarkably homogenous in choosing a minimum of a 50% 
decrease in HAMD scores as responder criterion. Finally, meta-regression allowed to identify factors 
that need to be considered by future research in this area. Nevertheless, a number of limitations should 
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be mentioned. First, our search yielded very few studies investigating central HPA markers as predictors 
of antidepressant treatment response. As a result of this, the null-findings of these particular meta-
analyses need to be interpreted with caution. Second, it is a frequent finding that patients with 
melancholic depression are characterised by hypercortisolaemia, while patients with atypical symptoms 
exhibit hypocortisolaemia (Chrousos, 2009). Unfortunately, only a handful of studies reported whether 
they conflated diagnostic subtypes of depression, which prevented us from investigating whether our 
findings are exclusive to a specific group of patients. Similarly, patients with psychotic symptoms show 
greater degrees of hypercortisolaemia, and few studies explicitly comment on the proportion of patients 
with such symptoms. Third, there was a lack of information on whether patients were affected by early 
life or chronic stress. Again, this rendered it impossible to examine whether specific subgroups of 
patients, namely those with a stress-related aetiology (Heim et al., 2008), are particularly likely not to 
profit from treatment with antidepressants, or to have different HPA axis profiles. 
Taken together, this meta-analysis shows that it highly depends on the methodological quality 
of a study whether it is able to show that the more marked depressed patients’ hypercortisolaemia, the 
less likely they are to achieve a significant response to antidepressants. Studies employing basal HPA 
assessments are well-advised to use non-invasive HPA markers whenever possible. Promising new 
biomarkers may include hair cortisol, which allows for an estimate of long-term secretion over the course 
of several months (Stalder and Kirschbaum, 2012), and potentially fingernail cortisol, measuring periods 
of several weeks (Izawa et al., 2015). In addition, it seems sensible for studies interested in post-
challenge HPA markers to select patients that are unaffected by any major somatic or mental illness 
except MDD. We also hope that our findings will prompt further research to add to the scant body of 
literature on central HPA markers and treatment response, and to explore the role of symptomatic and 
aetiological subtypes of depression. This may aid the ultimate goal of identifying patients that are at risk 
of not responding to fist-line treatments and might require alternative or adjuvant therapies. 
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Figure 1 Forest plot of central HPA predictors of antidepressant response; individual effect sizes are 
reported as standardised mean differences (SMD) between non-responders and responders and 95% 
confidence intervals (CI), while mean effect sizes are reported as Hedge’s g; negative effect sizes 
indicate that non-responders had higher pre-treatment concentrations of the respective parameter when 
compared to responders; positive effect sizes indicate that non-responders had lower pre-treatment 
concentrations of the respective parameter when compared to responders; an increase in ACTH upon 
stimulation (e.g., with exogenous CRH) is generally considered adaptive, whereas a failure to suppress 
ACTH secretion (e.g., after dexamethasone administration) is considered maladaptive. AVP = arginine 
vasopressin; CRH = corticotropin-releasing hormone; ACTH = adrenocorticotropic hormone; HPA = 
hypothalamic-pituitary-adrenal 
Figure 2 Forest plot of peripheral HPA predictors of antidepressant response; individual effect sizes are 
reported as standardised mean differences (SMD) between non-responders and responders and 95% 
confidence intervals (CI), while mean effect sizes are reported as Hedge’s g; negative effect sizes 
indicate that non-responders had higher pre-treatment concentrations of the respective parameter when 
compared to responders; positive effect sizes indicate that non-responders had lower pre-treatment 
concentrations of the respective parameter when compared to responders; an increase in cortisol upon 
stimulation (e.g., with exogenous CRH) is generally considered adaptive, whereas a failure to suppress 
cortisol (e.g., after dexamethasone administration) is considered maladaptive. CBG = corticosteroid 
binding globulin; CRH = corticotropin-releasing hormone; HPA = hypothalamic-pituitary-adrenal 
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Table 1 Characteristics of included studies on hypothalamic-pituitary-adrenal (HPA) functioning in 
depressed non-responders vs. responders to antidepressant treatment 
No. Study Sample (incl. 
extracted sample 
size) 
HPA 
measure 
Antidepressant Response 
rate 
Quality 
rating 
1 Park, 2015 N=51 (82% female) 
Inclusionary criteria: 
MDD according to the 
SCID 
Exclusionary criteria: 
abnormal laboratory 
tests, psychotic 
features, suicidal 
ideation, treatment 
with antidepressant 
or anti-anxiety drugs 
within 1 month 
Basal ACTH, 
basal 
cortisol 
(plasma) 
Escitalopram 63% 
(HAMD 
decrease 
of  50% 
or HAMD 
score < 
10) 
6/14 
2 Ruhe, 2015 N=55 (total sample: 
66% female) 
Inclusionary criteria: 
MDD according to the 
SCID, HAMD score > 
18 
Exclusionary criteria: 
neurological 
impairments, primary 
CAR (saliva) Paroxetine 31% 
(HAMD 
decrease 
of  50%) 
6/14 
21 
substance abuse, 
bipolar disorder, 
psychotic features, 
severe suicidal 
ideation, primary 
anxiety disorder, 
pregnancy, 
antidepressant intake 
within 1 month, > 1 
antidepressant for 
present episode, 
drugs affecting HPA 
functioning 
3 Yin, 2015, 
Zhang, 2014 
N=290 (51% female) 
Inclusionary criteria: 
MDD according to the 
DSM-IV, HAMD 
score > 18 
Exclusionary criteria: 
major medical 
disorders, abnormal 
laboratory tests, 
other mental 
disorders, 
pregnancy, 
antidepressant intake 
within 2 weeks 
Basal ACTH, 
basal 
cortisol 
(blood) 
Citalopram, 
fluoxetine, 
paroxetine, 
sertraline 
76% 
(HAMD 
decrease 
of  50%) 
8/14 
22 
(fluoxetine: 1 month), 
history of ECT 
4 Sarubin, 
2014 
N=28 (39% female) 
Inclusionary criteria: 
MDE according to the 
SCID 
Exclusionary criteria: 
somatic or mental 
illnesses, previous 
non-response to 
escitalopram or 
intolerance 
Cortisol after 
DEX/CRH 
test (blood) 
Escitalopram 64% 
(HAMD 
decrease 
of  50%) 
7/14 
5 Ventura-
Junca, 2014 
N=122 (total sample: 
97% female) 
Inclusionary criteria: 
MDD according to the 
MINI, HAMD score ≥ 
15 
Exclusionary criteria: 
medical or 
neurological 
illnesses, infections, 
abnormal thyroid 
function, 
hypertension, current 
substance abuse or 
comorbid mental 
Basal 
cortisol, 
cortisol after 
DST (saliva) 
Fluoxetine 55% 
(HAMD 
decrease 
of  50%) 
8/14 
23 
disorders, 
pregnancy, 
breastfeeding, 
medication intake 
within 2 months, 
history of treatment-
resistance 
6 Carvalho, 
2013 
N=19 (74% female) 
Inclusionary criteria: 
primary affective 
disorder according to 
the ICD-10, HAMD 
score ≥ 16, history of 
treatment-resistance 
Exclusionary criteria: 
significant physical 
illness, alcohol 
dependence, 
pregnancy, lactation, 
heavy smoking, 
drugs affecting 
endocrine or immune 
functioning within 1 
month, switch in 
medication within 2 
weeks, 
hypersensitivity to 
corticosteroid use 
Basal 
cortisol 
(plasma) 
Specialist 
inpatient 
treatment 
32% 
(HAMD 
decrease 
of  50%) 
3/14 
24 
7 Bschor, 2012 N=30 (80% female) 
Inclusionary criteria: 
MDD according to the 
SCID, HAMD score ≥ 
15 
Exclusionary criteria: 
somatic conditions 
influencing mineralo- 
or glucocorticoid 
functioning, organic 
brain disease, 
alcohol abuse or 
dependency, 
schizophrenia or 
schizoaffective 
disorder, bipolar 
disorder, pregnancy, 
lactation, intake of 
psychotropic drugs 
within 1 week (except 
diazepam) 
ACTH after 
DST, ACTH 
after 
DEX/CRH 
test, cortisol 
after DST, 
cortisol after 
DEX/CRH 
test (plasma) 
Citalopram 77% 
(HAMD 
decrease 
of  50%) 
8/14 
8 Soledad 
Rojas, 2011 
N=34 (71% female) 
Inclusionary criteria: 
MDD according to the 
MINI 
Exclusionary criteria: 
infections, abnormal 
Basal 
cortisol, 
cortisol after 
DST (saliva) 
Venlafaxine 77% 
(HAMD 
decrease 
of  50%) 
8/14 
25 
thyroid function, 
hypertension, other 
mental illnesses, 
pregnancy, nursing, 
oral contraceptives, 
hormone 
replacement, 
antidepressants or 
mood stabilisers 
within 1 month 
9 Deuschle, 
2010 
N=75 (65% female) 
Inclusionary criteria: 
depression according 
to the DSM-IV, 
HAMD score ≥ 18 
Exclusionary criteria: 
current substance 
abuse, lifetime 
schizophrenia or 
bipolar disorder, 
dieting, antidiabetic 
drugs, lipid-lowering 
drugs, fluoxetine or 
injectable 
antipsychotic drugs, 
psychotropics within 
1 week 
Basal 
cortisol 
(saliva) 
Mirtazapine, 
venlafaxine 
45% 
(HAMD 
score  7) 
4/14 
26 
10 Papakostas, 
2010 
N=17 (59% female) 
Inclusionary criteria: 
MDD according to the 
SCID, HAMD score ≥ 
15, using effective 
contraception 
Exclusionary criteria: 
unstable physical 
disorder, lifetime 
history of organic 
mental disorder, 
psychotic disorder, or 
mania, psychotic 
features, significant 
risk of suicide, 
pregnancy, 
breastfeeding, oral 
steroids or steroid 
inhibitors, 
antidepressants, 
adverse reaction to 
study drug, history of 
treatment-resistance 
Basal 
cortisol, 
cortisol after 
buspirone 
challenge 
(saliva) 
Citalopram 47% 
(HAMD 
decrease 
of  50%) 
6/14 
11 Paslakis, 
2010 
N=10 (0% female) 
Inclusionary criteria: 
MDD according to the 
DSM-IV, melancholic 
ACTH after 
DST, ACTH 
after 
DEX/CRH 
test, cortisol 
Fluoxetine 60% 
(HAMD 
decrease 
of  10 
points) 
7/14 
27 
subtype, HAMD 
score ≥ 18 
Exclusionary criteria: 
relevant physical 
illness, other mental 
disorders, 
psychotropics within 
1 week 
after DST, 
cortisol after 
DEX/CRH 
test (blood) 
12 Schüle, 2010, 
2009 
N=23 (83% female) 
Inclusionary criteria: 
MDE according to the 
SCID, melancholic 
subtype, HAMD 
score ≥ 18 
Exclusionary criteria: 
major medical illness, 
bipolar disorder, 
other mental 
disorders, 
pregnancy, oral 
contraceptives, 
angiotensin-
converting enzyme 
inhibitors, oral 
steroids, hormonal 
replacement, 
psychotropic drugs 
Basal 
cortisol 
(plasma) 
Mirtazapine 52% 
(HAMD 
decrease 
of  50%) 
10/14 
28 
within 5 days (except 
chloralhydrate) 
13 Juruena, 
2009 
N=45 (82% female) 
Inclusionary criteria: 
MDD according to the 
SCID, history of 
treatment-resistance 
Exclusionary criteria: 
significant physical 
illness, viral illness 
within 2 weeks, 
alcohol dependence, 
organic cause for 
MDD, psychotic 
symptoms unrelated 
to the MDE, bipolar 
disorder, heavy 
smoking, pregnancy, 
lactation, steroid use, 
hypersensitivity to 
corticosteroids, 
switch in medication 
regimen within 7 days 
Cortisol after 
prednisolone 
test (saliva) 
Specialist 
inpatient 
treatment 
53% 
(HAMD 
decrease 
of  50%) 
5/14 
14 Markopoulou, 
2009 
N=28 (79% female) 
Inclusionary criteria: 
MDD according to the 
Basal 
cortisol 
(plasma) 
Specialist 
inpatient 
treatment 
50% 
(HAMD 
decrease 
of  50%) 
5/14 
29 
SCID, history of 
treatment-resistance 
Exclusionary criteria: 
organic cause for 
MDD, excess alcohol 
use 
15 Heiser, 2008 N=24 (38% female) 
Inclusionary criteria: 
MDD according to the 
SCID 
Exclusionary criteria: 
infectious, 
autoimmune, allergic, 
neoplastic, or 
endocrine diseases, 
heart or brain infarct 
or surgery within 3 
months, drug abuse, 
other mental 
disorders, 
pregnancy, 
antipsychotics within 
6 months, 
antidepressants 
within 6 weeks 
Basal 
cortisol 
(plasma) 
Amitriptyline 58% 
(HAMD 
and 
MADRS 
decrease 
of  50%) 
8/14 
16 Schüle, 2006 N=40 (58% female) ACTH after 
DEX/CRH 
Mirtazapine, 
reboxetine 
65% 9/14 
30 
Inclusionary criteria: 
MDE according to the 
SCID, HAMD score ≥ 
18 
Exclusionary criteria: 
major medical 
illnesses, bipolar 
disorder, other 
mental disorders, 
pregnancy, oral 
contraceptives, 
psychotropic drugs 
within 5 days (except 
chloralhydrate) 
test 
(plasma), 
cortisol after 
DEX/CRH 
test (serum) 
(HAMD 
decrease 
of  50%) 
17 Weber-
Hamann, 
2006 
N=80 (69% female) 
Inclusionary criteria: 
MDE according to the 
DSM-IV, HAMD 
score ≥ 18 
Exclusionary criteria: 
current substance-
related disorders, 
lifetime 
schizophrenia, 
bipolar disorder, 
atypical features, 
dieting, antidiabetic 
drugs, lipid-lowering 
Basal 
cortisol 
(saliva) 
Amitriptyline, 
paroxetine 
64% 
(HAMD 
decrease 
of  50% 
or HAMD 
score < 7) 
5/14 
31 
drugs, psychotropics 
within 1 week 
18 Nikisch, 2005 N=21 (57% female) 
Inclusionary criteria: 
MDD according to the 
DSM-IV 
Exclusionary criteria: 
serious medical 
illnesses, ongoing 
lithium treatment, 
drugs that could 
interfere with central 
nervous amine 
metabolites within 1 
week, ECT within 4 
weeks, previous 
participation in 
clinical trial 
(citalopram) 
CRH (CSF) Citalopram 52% 
(HAMD 
decrease 
of  50%) 
5/14 
19 Rao, 2005 N=20 (50% female) 
Inclusionary criteria: 
MDD according to the 
SCID, HAMD score ≥ 
15 
Exclusionary criteria: 
neurological 
condition, medical 
Basal 
cortisol, 
cortisol after 
bupropion 
challenge 
(8h 
nocturnal 
urine) 
Bupropion 55% 
(HAMD 
decrease 
of  50%) 
7/14 
32 
illness, substance 
use disorder within 6 
months, psychotic 
disorder, bipolar 
disorder, active 
suicidal ideation or 
recent suicide 
attempt, primary 
anxiety disorder, 
anorexia/bulimia 
nervosa, history of 
sleep disorders, 
pregnancy, 
psychotropics within 
1 month (2 months 
for fluoxetine), prior 
use of bupropion 
20 Schüle, 2005 N=20 (60% female) 
Inclusionary criteria: 
MDE according to the 
DSM-IV, HAMD 
score ≥ 18 
Exclusionary criteria: 
major medical 
illnesses, bipolar 
disorder, other 
mental disorders, 
pregnancy, oral 
contraceptives, 
ACTH after 
TRH test, 
ACTH after 
T3/TRH test 
(plasma), 
cortisol after 
TRH test, 
cortisol after 
T3/TRH test 
(serum) 
Sertraline 50% 
(HAMD 
decrease 
of  50%) 
7/14 
33 
psychotropic drugs 
within 5 days (except 
chloralhydrate) 
21 Jahn, 2004 N=30 (53% female) 
Inclusionary criteria: 
MDD according to the 
DSM-IV, HAMD 
score ≥ 18, using 
effective 
contraception 
Exclusionary criteria: 
serious medical 
conditions, drug 
abuse, other axis I 
disorders, 
pregnancy, nursing, 
medication within 5 
days (except anti-
hypertensives) 
Basal ACTH, 
basal 
cortisol 
(plasma) 
Nefazodone, 
fluvoxamine 
33% 
(HAMD 
decrease 
of  50%) 
7/14 
22 Young, 2004 N=20 (100% female) 
Inclusionary criteria: 
MDD according to the 
SCID, HAMD score ≥ 
20, premenopausal 
Exclusionary criteria: 
other axis I disorders 
(except anxiety 
ACTH after 
metyrapone 
challenge 
(blood) 
Fluoxetine 40% 
(HAMD 
decrease 
of  50%) 
7/14 
34 
disorders), failed trial 
of fluoxetine within 1 
year 
23 Deuschle, 
2003 
N=81 (70% female) 
Inclusionary criteria: 
MDE according to the 
DSM-IV, HAMD 
score ≥ 18 
Exclusionary criteria: 
lifetime 
schizophrenia or 
bipolar disorder, 
current substance-
related disorder, 
psychotropic 
medication within 6 
days 
CBG 
(serum) 
Amitriptyline, 
paroxetine 
68% 
(HAMD 
decrease 
of  50%) 
4/14 
24 Heuser, 1998 N=18 (total sample: 
70% female) 
Inclusionary criteria: 
MDE according to the 
DSM-III-R 
Exclusionary criteria: 
mood-incongruent 
psychotic features, 
previous intake of 
fluoxetine, 
AVP, CRH 
(CSF) 
Amitriptyline 50% 
(HAMD 
decrease 
of  50%) 
4/14 
35 
psychotropics within 
5 days 
25 Deuschle, 
1997 
N=16 (sex 
distribution not 
reported) 
Inclusionary criteria: 
MDE according to the 
DSM-III-R, HAMD 
score ≥ 18 
Exclusionary criteria: 
physical illness, 
antipsychotics within 
6 months 
Cortisol after 
DST, cortisol 
after 
DEX/CRH 
(blood) 
Doxepin 56% 
(HAMD 
decrease 
of  50%) 
5/14 
26 Kin, 1997 N=35 (sex 
distribution not 
reported) 
Inclusionary criteria: 
MDD according to the 
DSM-III-R, HAMD 
score ≥ 18 
Exclusionary criteria: 
psychotropics within 
7 days 
Cortisol after 
DST 
(plasma) 
Nortriptyline 31% 
(HAMD 
decrease 
of  50%) 
3/14 
36 
27 Ravindran, 
1997 
N=30 (63% female) 
Inclusionary criteria: 
MDD according to 
RDC and the DSM-III 
Exclusionary criteria: 
significant physical 
illness, psychotropic 
drugs within 4 days 
Cortisol after 
DST 
(plasma) 
Imipramine 50% 
(HAMD 
decrease 
of  50% 
and 
HAMD 
score < 
10) 
2/14 
28 Heuser, 1996 N=39 (82% female) 
Inclusionary criteria: 
MDE according to the 
DSM-III-R, HAMD 
score ≥ 18 
Exclusionary criteria: 
major medical illness, 
major mental 
disorders, slow-
release 
antipsychotics, 
benzodiazepines, 
barbiturates, lithium, 
or carbamazepine for 
> 6 months, 
psychotropics within 
5 days 
ACTH after 
DST, ACTH 
after 
DEX/CRH 
test, cortisol 
after DST, 
cortisol after 
DEX/CRH 
test (plasma) 
Amitriptyline 54% 
(HAMD 
decrease 
of  50% 
or HAMD 
score < 
10) 
7/14 
37 
29 Ravindran, 
1994 
N=30 (60% female) 
Inclusionary criteria: 
primary dysthymia 
according to the 
DSM-III-R 
Exclusionary criteria: 
significant medical 
illness, other mental 
disorders, 
psychotropics within 
1 week 
Cortisol after 
DST 
(plasma) 
Fluoxetine 83% 
(HAMD 
decrease 
of  50% 
and 
HAMD 
score  7) 
5/14 
30 Duval, 1993 N=57 (60% female) 
Inclusionary criteria: 
MDD according to the 
DSM-III-R 
Exclusionary criteria: 
bipolar disorder 
Cortisol after 
DST 
(plasma) 
Amitriptyline, 
fluoxetine, 
toloxatone 
46% 
(HAMD 
score < 8) 
5/14 
31 Peselow, 
1989 
N=66 (35%female) 
Inclusionary criteria: 
MDD according to the 
DSM-III, HAMD score 
≥ 18 
Exclusionary criteria: 
active medical 
illness, 
Cortisol after 
DST 
(plasma) 
Imipramine, 
paroxetine 
58% 
(HAMD 
decrease 
of  50% 
and BDI  
50%, or 
CGI  2) 
6/14 
38 
endocrinopathy, 
substance abuse 
32 Shunwei Li, 
1989 
N=11 (64% female) 
Inclusionary criteria: 
primary endogenous 
MDD according to 
RDC 
Exclusionary criteria: 
none reported 
Cortisol after 
DST 
(plasma) 
Amitriptyline, 
desipramine, 
imipramine, 
nortriptyline, 
phenelzine 
91% 
(HAMD 
decrease 
of  50% 
and 
HAMD 
score < 
10) 
3/14 
33 Georgotas, 
1986 
N=52 (total sample: 
58% female) 
Inclusionary criteria: 
MDD according to 
RDC, HAMD score ≥ 
16 
Exclusionary criteria: 
serious neurological 
disorders, dementia, 
drug or alcohol 
dependence, active 
suicidality, mental 
retardation, other 
major mental 
disorders, urinary 
retention, glaucoma, 
antipsychotics, 
lithium, 
Cortisol after 
DST 
(plasma) 
Nortriptyline, 
phenelzine 
58% 
(HAMD 
score  
10) 
7/14 
39 
carbamazepine, 
MAO inhibitors within 
1 year, drugs 
influencing 
dexamethasone 
pharmacokinetics, 
antidepressants 
within 1 week, super-
sensitivity to 
antidepressants 
34 Lu, 1986 N=5 (60% female) 
Inclusionary criteria: 
primary endogenous 
MDD according to the 
DSM-III, HAMD score 
≥ 18 
Exclusionary criteria: 
abnormal physical or 
laboratory testing, 
body weight within 
20% of ideal weight, 
lifetime slow-release 
antipsychotics, ECT, 
insulin shock therapy, 
or corticosteroids, 
antipsychotics or 
antidepressants 
within 1 month, any 
Basal 
cortisol, 
cortisol after 
DST 
(plasma) 
Imipramine 80% 
(HAMD 
score < 
14) 
6/14 
40 
medication within 1 
week 
35 Modai, 1986 N=32 (total sample: 
63% female) 
Inclusionary criteria: 
MDE according to the 
DSM-III 
Exclusionary criteria: 
physical illness 
interfering with the 
DST 
Cortisol after 
DST (blood) 
Amitriptyline, 
chlorimipramine, 
phenelzine 
63% 
(BDI 
decrease 
of > 10 
points) 
3/14 
36 Coppen, 
1985 
N=44 (59% female) 
Inclusionary criteria: 
MDD according to 
RDC, HAMD score ≥ 
16 
Exclusionary criteria: 
drugs influencing 
dexamethasone 
kinetics 
Cortisol after 
DST 
(plasma) 
Amitriptyline, 
clomipramine, 
dothiepin, 
imipramine, 
mianserin, 
nomifensine, 
tranylcypromine, 
tryptophan, 
zimeldine 
52% 
(HAMD 
decrease 
of  50%) 
5/14 
37 Gerken, 1985 N=7 (100% female) 
Inclusionary criteria: 
primary endogenous 
MDD according to the 
DSM-III 
Cortisol after 
DST (blood) 
Amitriptyline, 
lofepramine 
71% 
(HAMD 
score  6) 
7/14 
41 
Exclusionary criteria: 
medical illness, 
cerebral atrophy, 
alcohol withdrawal, 
pregnancy, 
significant weight 
loss, steroid-
containing drugs, 
anticonvulsive drugs, 
barbiturates 
38 Arato, 1984 N=74 (100% female) 
Inclusionary criteria: 
MDD according to 
RDC, HAMD score ≥ 
18 
Exclusionary criteria: 
medical illnesses 
influencing the DST, 
drugs 
Cortisol after 
DST (blood) 
Amitriptyline, 
dipenzepine, 
imipramine, 
maprotiline 
64% 
(HAMD 
decrease 
of  50%) 
3/14 
39 Frank, 1984 N=34 (82% female) 
Inclusionary criteria: 
primary recurrent 
unipolar depression 
according to RDC, 
HAMD score ≥ 15 
and Raskin 
Basal 
cortisol 
(serum) 
Combined 
treatment 
68% 
(HAMD 
score  
10) 
7/14 
42 
Depression Scale 
score ≥ 7 
Exclusionary criteria: 
significant 
cardiovascular, renal, 
liver, or endocrine 
disease, epilepsy, 
glaucoma, organic 
brain syndrome, 
lifetime Briquet’s 
disorder, panic 
disorder, generalised 
anxiety disorder, 
obsessive-
compulsive disorder, 
phobic disorder, or 
antisocial personality 
disorder, mental 
retardation, 
psychotropics within 
14 days, medical 
history precluding the 
use of tricyclic 
antidepressants 
ACTH = adrenocorticotropic hormone, AVP = arginine vasopressin, BDI = Beck Depression Inventory, 
CAR = cortisol awakening response, CBG = corticosteroid-binding globulin, CGI = Clinical Global 
Improvement, CRH = corticotropin releasing hormone, CSF = cerebrospinal fluid, DEX/CRH = 
dexamethasone/corticotropin releasing hormone, DST = dexamethasone suppression test, ECT = 
electroconvulsive therapy, GR = glucocorticoid receptor, HAMD = Hamilton Rating Scale for Depression, 
HPA = hypothalamic-pituitary-adrenal, IDS-C = Inventory of Depressive Symptoms – Clinician-Rated, 
43 
MADRS = Montgomery-Asberg Depression Rating Scale, MAO = monoamine-oxidase, MDE = major 
depressive episode, MDD = major depressive disorder, MINI = Mini International Neuropsychiatric 
Interview, RDC = Research Diagnostic Criteria, SCID = Structured Clinical Interview for the Diagnostic 
and Statistical Manual 
 
 
